	Discussify and a location another a identify the second size where his size
1	Diversity and selection analyses identify transmission-blocking
2	antigens as the optimal vaccine candidates in <i>Plasmodium falciparum</i>
3	
4	Ilinca I. Ciubotariu ¹ , Bradley K. Broyles ¹ , Shaojun Xie ² , Jyothi Thimmapuram ² , Mulenga C. Mwenda ³ ,
5	Brenda Mambwe ³ , Conceptor Mulube ³ , Japhet Matoba ⁴ , Jessica L. Schue ⁵ , William J. Moss ^{6,7} , Daniel J.
6	Bridges ⁸ , Qixin He ^{1*} , and Giovanna Carpi ^{1,9*}
7	
8	¹ Department of Biological Sciences, Purdue University, West Lafayette, Indiana, USA
9	² Bioinformatics Core, Purdue University, West Lafayette, Indiana, USA
10	³ PATH-Malaria Control and Elimination Partnership in Africa (MACEPA), National Malaria Elimination
11	Centre, Lusaka, Zambia
12	⁴ Macha Research Trust, Choma, Zambia
13	⁵ Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore,
14	Maryland, USA
15	⁶ The W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Malaria
16	Research Institute, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
17	⁷ Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland,
18	USA
19	⁸ PATH, Lusaka, Zambia
20	⁹ Purdue Institute of Inflammation, Immunology and Infectious Disease, West Lafayette, Indiana, USA
21	* Joint senior authors
22	
23	Corresponding authors:
24	Correspondence to Giovanna Carpi (gcarpi@purdue.edu) and Qixin He (heqixin@purdue.edu).
25	
26	

27 Summary

28 Background

29 A highly effective vaccine for malaria remains an elusive target, at least in part due to the under-

30 appreciated natural parasite variation. This study aimed to investigate genetic and structural variation,

31 and immune selection of leading malaria vaccine candidates across the *Plasmodium falciparum*'s life

32 cycle.

33 Methods

34 We analyzed 325 *P. falciparum* whole genome sequences from Zambia, in addition to 791 genomes from

35 five other African countries available in the MalariaGEN Pf3k Rdatabase. Ten vaccine antigens spanning

36 three life-history stages were examined for genetic and structural variations, using population genetics

37 measures, haplotype network analysis, and 3D structure selection analysis.

38 Findings

39 Among the ten antigens analyzed, only three in the transmission-blocking vaccine category display *P*.

40 falciparum 3D7 as the dominant haplotype. The antigens AMA1, CSP, MSP1₁₉ and CelTOS, are much

41 more diverse than the other antigens, and their epitope regions are under moderate to strong balancing

42 selection. In contrast, *Rh5*, a blood stage antigen, displays low diversity yet slightly stronger immune

43 selection in the merozoite-blocking epitope region. Except for *CeITOS*, the transmission-blocking antigens

44 Pfs25, Pfs48/45, Pfs230, Pfs47, and Pfs28 exhibit minimal diversity and no immune selection in epitopes

45 that induce strain-transcending antibodies, suggesting potential effectiveness of 3D7-based vaccines in

46 blocking transmission.

47 Interpretations

48 These findings offer valuable insights into the selection of optimal vaccine candidates against *P*.

49 falciparum. Based on our results, we recommend prioritizing conserved merozoite antigens and

50 transmission-blocking antigens. Combining these antigens in multi-stage approaches may be particularly

51 promising for malaria vaccine development initiatives.

52 Funding

3

Furdue Department of Biological Sciences; Puskas Memorial Fellowship; National Institute of Allergy and
 Infectious Diseases (U19AI089680).

55 **Research in context**

56 Evidence before this study

57 Decades of research on the most virulent malaria parasite, *Plasmodium falciparum*, have yielded multiple

58 antigen candidates of pre-erythrocytic, blood-stage, and transmission-blocking vaccines in varying stages

59 of development from preclinical development to more advanced clinical trials. The malaria vaccine,

60 RTS,S/AS01, which was constructed using the C-terminal and NANP repeat region of the

61 Circumsporozoite Protein (CSP) from the African reference strain 3D7, was approved and recommended

62 for use in 2021. However, the vaccine's lower efficacy is likely a result of the genetic polymorphism of the

63 target antigen shown by studies on natural variation in CSP. Similarly, another more recent pre-

64 erythrocytic vaccine, R21/Matrix-M, showed great promise in clinical trials and was recommended in late

65 2023 by the WHO for use for prevention of malaria in children, but is also multi-dose and CSP-based. To

66 maximize vaccine efficacy, it would be more strategic to first understand diversity and variation of

67 antigens across the three types of vaccine classes, targeting various stages of the *P. falciparum* life cycle.

68 Previous studies have reported analyses of vaccine candidate antigens but were mostly limited to pre-

69 erythrocytic and blood-stage antigens, with less focus on transmission-blocking antigens. These studies

70 revealed that most of the pre-erythrocytic and blood-stage antigens are of high diversity due to balancing

71 selection, posing challenges for vaccine design to encompass the antigenic variation.

A search conducted on PubMed on April 1, 2024, for relevant published research which used the terms "malaria vaccine", "*Plasmodium falciparum*" [not "*vivax*"], "selection" and "diversity" yielded 48 studies between 1996 and the present day, with only 14 published studies in the past 3 years. This emphasizes the need for more studies assessing genetic diversity and selection of potential *P. falciparum* vaccine candidates to aid in more effective vaccine development efforts. A similar search with the terms "transmission-blocking vaccine", "malaria", "*Plasmodium falciparum*", not "*vivax*", "selection" and

4

"diversity" without any date or language restrictions revealed three relevant studies. This warrants future
 studies to explore transmission-blocking vaccines in this context.

80 Added value of this study

By comparing the genetic and structural analyses of transmission-blocking antigens with pre-erythrocytic and blood-stage antigens, we identify promising *P. falciparum* vaccine antigens characterized by their conservation with low balancing selection and the presence of infection/transmission-blocking epitopes, which are essential for informing the development of new malaria vaccines. This comprehensive workflow can be adopted for studying the genetic and structural variation of other *P. falciparum* vaccine targets before developing the next generation of malaria vaccines for effectiveness against natural parasite populations.

88 Implications of this study

- 89 Our suggested strategies for designing malaria vaccines include two possible approaches. We
- 90 emphasize the development of a multi-stage vaccine that combines critical components such as anti-
- 91 merozoite (*Rh5*) and transmission-blocking antigens (*Pfs25*, *Pfs28*, *Pfs48/45*, *Pfs230*). Alternatively, we
- 92 suggest the creation of transmission-blocking vaccines specifically targeting *Pfs25*, *Pfs28* and *Pfs48/45*.
- 93 These innovative approaches show great potential in advancing the development of more potent and
- 94 effective malaria vaccines for the future.

95 Introduction

For preventing and controlling many infectious diseases, vaccines are vital tools that increase immunity, leading to reduced disease severity, incidence, and transmission. For malaria, a vector-borne disease caused by *Plasmodium* species parasites, vaccine strategies can be characterized by the three main parasite life-cycle stages that they target (Fig. 1). Firstly, pre-erythrocytic vaccines target sporozoites inoculated by *Anopheles* mosquitoes into the human skin before they reach the liver or infected hepatocytes, with the aim of preventing initial infection^{1,2}. Some pre-erythrocytic subunit vaccine candidates^{3,4} for *P. falciparum* include the first licensed malaria vaccine RTS,S/AS01⁵, low-dose

5

103 R21/Matrix-M vaccine (currently approved for use in some countries⁶), and the full-length *CSP*⁷. Blood-104 stage vaccines predominantly target merozoites or infected erythrocytes to prevent replication and clinical 105 illness, and some candidates include *AMA1*, *MSP1*, and *Rh5*^{3,8}. Transmission-blocking vaccines target 106 antigens expressed in the gametes and ookinete stages in the mosquito midgut; this vaccine type induces 107 antibodies in humans that impair the parasite's development inside the mosquito and thus prevent 108 subsequent transmission. Some examples of transmission-blocking vaccine candidates are *Pfs25*, 109 *Pfs230*, and *Pfs48/45*^{3,9,10}.

110 To date, among the numerous preclinical and clinical trials of these classes of vaccines, RTS,S and R21 111 are the only two malaria vaccine licensed and recommended by the WHO. The former is approved for 112 widespread use among children in sub-Saharan Africa and other regions with moderate to high P. 113 falciparum malaria transmission^{5,11-14} and the latter by regulators in Ghana, Nigeria, and Burkina Faso^{6,15}. 114 While this is a tremendous breakthrough for the field considering the complexity of the parasite life cycle 115 and the correspondingly large number of protein-coding genes (>5,000) in the Plasmodium genome¹⁶, 116 there is a wealth of vaccine targets¹⁷⁻²⁰. Despite the large number, about 60% of the genes code for 117 putative proteins²¹ and have unknown function^{16,22}, which poses an enormous challenge, and many of 118 these 5300+ protein coding genes do not make attractive vaccine targets due to expression patterns, 119 localization, high genetic variability, etc., and candidates must be experimentally validated for vaccine 120 development²³. Yet, despite decades of effort, noticeably little progress past early phase clinical trials for 121 many of these other targets^{24,25}. Furthermore, the RTS,S vaccine shows only modest efficacy ranging 122 from 30% to 40% that wanes with time and requires four doses to reduce severe malaria by 30%^{12,26-28}. 123 This low efficacy has been attributed to the high genetic diversity and many polymorphic residues of the 124 target antigen, CSP ^{12,24,29}. Notably, RTS,S was developed using a standard laboratory strain (P. 125 falciparum 3D7), which originates from Africa but is not highly representative³⁰ and has low frequency 126 within many parasite populations^{29,31-33}. This underlines the need to consider CSP's functional importance 127 as well as the natural variation in the population, especially in epitope regions^{25,34}, when designing a 128 vaccine. In recent years, vaccines based on regions of conserved or semi-conserved epitopes are 129 emerging in other important yet antigenically diverse pathogens such as influenza virus and 130 meningococcus³⁵⁻³⁷.

6

131 With the release of thousands of publicly available P. falciparum whole genome sequences (WGS), it is 132 possible to study the natural genetic and functional variation of targets for malaria vaccine candidate 133 antigens, yet, to date few studies have done so^{34,38-40}. Two recent studies reported comprehensive 134 analyses of vaccine candidate antigens^{25,41}, but were focused primarily on pre-erythrocytic and blood-135 stage antigens, with limited inclusion of transmission-blocking antigens. Here, we aimed to characterize 136 the natural genetic and structural variation of ten P. falciparum vaccine antigens spanning the three 137 different vaccine classes, including transmission-blocking antigens. We focused on Africa which carries 138 the heaviest burden of malaria, and augmented parasite genomic data from Zambia, where malaria 139 continues to be endemic and a major public health with over 8 million cases and 1300 deaths reported in 140 2022⁴².

141 Methods

142 Ethics Statement

143 The parents or legal guardians provided parental permission for study participants and this study was 144 conducted with the approval of the Biomedical Research Ethics Committee from the University of Zambia 145 (Ref 011-02-18) and from the Zambian National Health Research Authority.

146

147 Sample Selection and Processing

148 This work is a secondary analysis of a larger parent study focused on understanding malaria transmission 149 across Zambia and establishing a baseline for parasite genetic metrics for this country that are 150 informative about transmission intensity, genetic relatedness between parasites, and selection⁴³. Briefly, 151 dried blood spot (DBS) samples were collected as part of the 2018 Zambia Malaria Indicator Survey 152 (MIS), which used a nationally representative two-stage stratified clustering sampling strategy to obtain 153 samples across Zambia for the estimation of malaria prevalence⁴⁴. The 2018 MIS included DBS samples 154 from children under the age of 5 from 179 standard enumeration areas from across ten provinces, with 155 high transmission provinces oversampled⁴⁴. Due to undersampling in the low transmission provinces 156 (Central, Lusaka and Southern), we augmented the DBS samples from the Zambia 2018 MIS with DBS

7

- 157 samples from Southern Province collected in the community surveillance program from the Southern and
- 158 Central Africa International Centers of Excellence for Malaria Research (ICEMR)⁴⁵. These additional
- 159 samples temporally matched the MIS (from 2018-2019) and were collected as part of a longitudinal cohort
- 160 study conducted to understand sources of focal transmission from an area with an expected relatively
- 161 high number of incident malaria cases.
- 162 In total we included 459 PET-PCR positive *P. falciparum* samples from seven provinces⁴³ and additional
- 163 28 PCR positive *P. falciparum* samples from Southern Province for sequencing. The samples were
- processed for genomic DNA extraction as previously described^{43,46} and then genomic library preparation,
- 165 parasite enrichment and sequencing were carried out.
- 166

167 Whole-Genome Sequencing

168 To selectively enrich and sequence whole *P. falciparum* genomes from DBS we used a 4-plexed hybrid

169 capture method previously described⁴³. Genomic library preparation, hybridization capture, and

170 sequencing was conducted at the Yale Center for Genomic Analysis (YCGA). Samples were sequenced

using 101 bp paired-end read sequencing on an Illumina NovaSeq 6000 with a target of 30 million reads

172 per sample.

173

174 Acquisition of Additional Genomic Data

175 To contextualize Zambian *P. falciparum* genome diversity within Africa, we included and analyzed 781

176 publicly available *P. falciparum* WGS data from 5 countries across West, Central, and East Africa

- 177 (Democratic Republic of the Congo, Ghana, Guinea, Malawi, and Tanzania) from the MalariaGEN Pf3k
- 178 project release 5.1 (https://www.malariagen.net/data/pf3k-5) and the MalariaGEN P. falciparum
- 179 Community Project (http://www.malariagen.net/resource/16). Raw Fastq files were downloaded from SRA
- 180 using pysradb (<u>https://github.com/saketkc/pysradb</u>)⁴⁷ and processed in the same way as the newly
- 181 sequenced WGS.

182

183 Read Mapping and Variant Identification

8

184 We identified *P. falciparum* genomic variation from whole genome sequence data using a bioinformatics

- pipeline previously described⁴⁸. Briefly, the Illumina paired-end reads were trimmed for low-quality bases
- 186 (Phred-scaled base quality <30) and mapped to the *P. falciparum* 3D7 reference genome
- 187 (ftp://ftp.sanger.ac.uk/pub/project/pathogens/gff3/2015-08/Pfalciparum.genome.fasta.gz) using BWA-
- 188 MEM v0.7.17⁴⁹. Aligned reads for the 1248 samples (487 from Zambia and 781 from Pf3k) were marked
- 189 for duplicates and sorted using Picard Tools 2.20.8. For variant calling only samples with >50% of the
- 190 regions spanning the selected antigens (Table 1) with >5X read coverage were included, resulting in a
- 191 total of 1092 *P. falciparum* WGS samples. Variants were called using GATK v4.1.4.1 following best
- 192 practices (<u>https://software.broadinstitute.org/gatk/best-practices</u>)^{50,51}. We applied GATK Base Quality
- 193 Score Recalibration using default parameters and using variants from the *P. falciparum* crosses 1.0
- 194 release as a set of known sites (ftp://www.malariagen.net/data/pf-crosses-1.0)⁵². GATK HaplotypeCaller

195 in GVCF mode was used to call single-sample variants (ploidy 2 and standard-min-confidence-threshold

- 196 *for calling* = 30), followed by GenotypeGVCFs to genotype the cohort. We restricted our analyses to
- 197 variants from the 14 nuclear chromosomes only, excluding variants from telomeric and hypervariable
- 198 regions (ftp://ngs.sanger.ac.uk/production/malaria/pf-crosses/1.0/regions-20130225.onebased.txt). We
- 199 further removed variants with VQSLOD <0 and SNPs with missingness >0.2. After variant filtering, we
- 200 scored 426,757 genome-wide SNPs across the 1092 samples.
- Variants were functionally annotated with SnpEff (version 4.3t) for genomic variant annotations and
 functional effect prediction⁵³.
- 203

204 Multiplicity of Infection

205 To ensure high quality haplotype reconstruction, we first determined the multiplicity of infection (MOI) for

206 each sample using within-sample F statistic (F_{WS})⁵⁴ implemented in the R moimix package (available

- 207 at https://github.com/bahlolab/moimix). Fws scores infections on a continuous scale of multiplicity, with
- infections having an Fws > 0.95 considered clonal (MOI=1), those with Fws < 0.95 and > 0.8 containing
- 209 two strains (MOI=2), and those with $F_{WS} < 0.8$ harboring more than two strains (MOI>2). F_{WS} metric
- 210 derived from the 426,757 genome-wide SNPs were used to stratify samples into single infections, two
- 211 infections or more than two infections.

9

212

213 Selection of Vaccine Candidate Antigens

- 214 Antigens were selected based on their inclusion¹⁴ in either two licensed and recommended malaria
- 215 vaccines (e.g. CSP)²⁸, clinical development in Phase I (e.g. AMA1, Rh5, MSP1, Pfs25, Pfs48/45, and
- 216 Pfs230)³, clinical development in Phase II (e.g. Rh5 and Pfs230)⁵⁵⁻⁵⁷, or their recognition as a promising
- vaccine target (e.g. *Pfs47*, *Pfs28*, and *CeITOS*)^{58,59}. The ten selected antigens encompassed all parasite
- 218 life cycle stages (Table 1 and Fig. 1), and genomic information and coordinates are provided in Table S1.
- 219

220 Haplotype Reconstruction

221 Vaccine target regions (Table S1) were extracted from the filtered VCF file (VQSLOD <0) in BED format

- using vcftools (version 0.1.16). Haplotypes were reconstructed using a custom code available at
- 223 https://github.com/giocarpi/Pf_capture_div_code, which converted the VCF file to FASTA format,
- 224 incorporating all variants (SNPs and INDELs) within coding sequences (CDS) relative to the *P. falciparum*
- 3D7 reference gene sequences. For a given variant position in a sample, a minimum read depth was
- required to be 5 for samples of MOI=1 and a minimum read depth of 10 for samples of MOI=2. A
- 227 minimum minor allele proportion for a heterozygous call to be made was set to 0.2. If the mean frequency
- of minor alleles was below 0.4, these minor alleles constituted a minor haplotype, which would be
- included in the following analyses; otherwise, the minor haplotype was not retained (according to paper²⁵
- and code). Samples failing read depth criteria were excluded from downstream analysis, as were
- samples containing one or more 'N' nucleotides.
- 232

233 Genetic Diversity Analysis

The software DNA Sequence Polymorphism (DnaSP) version 6.12.03 was used to calculate the number of unique haplotypes (h) of each respective vaccine candidate antigen in each country, the number of polymorphic sites (S), and the average number of pairwise nucleotide differences (k) between samples from within and between countries⁶⁰. Furthermore, we calculated the haplotype diversity (Hd) for each antigen, with 1 representing a population in which every haplotype is unique and 0 equating a population where each haplotype is identical. Nei's nucleotide diversity statistic⁶¹ (π) within each country and among

10

240 all samples was also calculated, which represents the average number of nucleotide differences between 241 haplotypes drawn from the same population. Tajima's D statistic values⁶¹⁻⁶³ were calculated using 242 Molecular Evolutionary Genetics Analysis (MEGA X) version 10.1.7 to measure selection (Tajima's D 243 values that are approximately zero occur in neutral conditions, >1 indicates balancing selection, and <1 244 represents purifying selection). Gaps in the multiple sequence alignments were treated as complete 245 deletion. To assess the genealogical relationships between the haplotypes found in Pf3k from African 246 countries and those from Zambia for each vaccine candidate antigen of interest, we constructed 247 haplotype networks based on the method by Templeton, Crandall, and Sing (TCS) using PopArt version 248 1.7^{64,65}.

249

250 Structural Analyses

251 Protein structures used for the downstream analyses were either selected from existing solved ones or 252 generated from AlphaFold2⁶⁶. PDB structures were retrieved from the Research Collaboratory for 253 Structural Bioinformatics (RCSB) database on 5/23/2023. The final solved structures to be used for each 254 protein were selected based on three criteria: 1) the structure was based on P. falciparum 3D7 reference 255 gene sequences; 2) most complete in terms of gene coverage; 3) resolved as many residues with 256 polymorphisms as possible. Often, the SNP-containing residues occurred in solvent-exposed loop regions 257 that were not resolved in published Protein Data Bank (PDB) structures. In these cases (i.e., AMA1, Rh5, 258 Pfs230 (D1, D2), Pfs25, MSP119) and the case of no solved structures for P. falciparum (i.e., Pfs47, 259 CeITOS), we assessed the gualities of AlphaFold2's predictions of these structures, that is whether the 260 RMSD is small or < 3 Å^{67,68} (Fig. S3). *Pfs230* (D1, D2), *Pfs25, Pfs4845*, and *MSP1*₁₉ were successfully 261 folded by AlphaFold2, agreeing with the native fold at or below 2 Å Root Mean Square Deviation (RMSD). 262 *Rh5* prediction was unable to meet this threshold, therefore we proceeded with the most complete solved 263 structure of Rh5 available. AMA1 structures were missing domain III, as well as missing resolution of 264 many residues in a loop of domain II (residues 351–389). AlphaFold2 was able to confidently predict 265 domain III and the overall structure (RMSD 0.36), but the missing loop residues of domain II were of low 266 confidence, and the placement of the loop disagreed with the resolved residues of this loop in solved

11

structures. For this reason, we proceeded with an AlphaFold2 model of *AMA1* including domain III but
excluding the low confidence loop region of domain II.

269 Pfs47 had no deposited structures. Hence, it was predicted entirely with AlphaFold2 with good confidence 270 (Fig. S3). CeITOS had no deposited structures for P. falciparum, but the P. vivax homolog has been 271 experimentally solved. We assessed a structure modeled with AlphaFold2 for P. falciparum CelTOS and 272 verified its fit to P. vivax (RMSD 1.59), trimming off residues outside the solved P. vivax structure. 273 AlphaFold2 structures were predicted on 3D7 reference sequences, utilizing the ColabFold⁶⁹ 274 pipeline (https://colab.research.google.com/github/sokrypton/ColabFold). Multiple sequence alignments 275 were performed with MMseqs2 searching through UniRef+Environmental datasets. For each protein, 276 three different structure models were run with six recycles and early stops at 100 PLDDT. Templates and 277 AMBER relaxation were set to "off". Models of rank one were chosen as final structures. For predicted 278 structures with solved references that needed loop or domain modeling, an agreement between predicted 279 and solved reference of 2 Å RMSD or less was deemed suitable for downstream analysis. For predicted 280 structures with no solved reference, a convergence of three models to a structure within 2 A RMSD 281 between three models was assessed as a confident prediction model.

282 All the available solved antibody-antigen structures of seven of ten vaccine target proteins were 283 obtained from RCSB (as of 7/12/23). Using a custom R script, we extracted interface residues between 284 the antibody and target protein that occur within 5 Å of each other. Pfs47 lacks antibody-antigen 285 structures, so we have included a known linear epitope (see Table 1). These interface residues were 286 sorted into bins for visualization purposes at 0, 1, 2, or 3+ antibody interfaces, to represent common 287 epitopes vs. infrequent and non-targeted residues. We consolidated identical antibodies with multiple 288 structures into a single record. This ensures that the count of epitopes involving each interface residue 289 only includes unique antibody contacts.

290

291 Calculation of 3D population genetics measures

292 To calculate spatially derived nucleotide diversity (π^*) and Tajima's D (D*) values, we utilized the

BiostructMap Python^{70,71} package, installed from <u>https://github.com/andrewguy/biostructmap</u>. The

294 package provides a method for mapping DNA sequence data to residues on protein structures, defining a

12

295	spatial neighborhood of the residue, and calculating the statistics using a three-dimensional (3D) sliding
296	window approach. In our study, we selected a 3D window with a radius of 15 Å, which represents the
297	maximum surface of an antibody-antigen binding site ⁷² . We chose not to apply a relative solvent
298	accessibility (RSA) filter and included all the residues within the radius of 15 Å, because polymorphisms
299	at buried residues could have structural effects on an epitope, and thus should be reflected in calculated
300	diversity and selection pressure.
301	
302	Role of the Funding Sources
303	The funders of the study had no role in the study design, data collection, data analysis, data

304 interpretation, writing of the manuscript, or the decision to submit for publication.

305 **Results**

306 Enhancing *P. falciparum* genomic diversity from African countries

307 We augmented 241 *P. falciparum* whole genome sequences previously reported⁴³ with an additional 84

308 genomes from Zambia, a malaria endemic country in South-Central Africa currently lacking *P. falciparum*

309 genomic representation in public databases. Combining these data with publicly available WGS

310 sequences from the MalariaGEN P. falciparum Community Project Consortium⁷³

311 (http://www.malariagen.net/resource/16), WGS data of 1248 *P. falciparum* samples from 6 African

312 countries were processed to obtain gene sequence haplotypes for ten antigens, with the final data set

313 consisting of 1092 samples after quality filtering (Table 1, Table 2) for population genetic analyses. To

314 ensure high-quality haplotype reconstruction, the multiplicity of infections (MOI) was determined using

 F_{WS}^{54} , and samples with a high multiplicity of infections (MOI>2) were removed. Overall, 44.2% (483) of

316 1092 African field samples were found to harbor more than two infections, with Malawi having the highest

percentage (50.8%), followed by Zambia (48.9%) (Fig. S2). Moreover, 17.6% of samples (192) had

318 MOI=2 and 38.2% (417) were characterized as MOI=1 (Fig. S2). Additionally, there was a mean of 457

319 (range:196-579) sequences per antigen when considering full-length genes for analysis, and a mean of

13

320 591 (range: 555-623) sequences per antigen when considering partial genes for those with specific

321 regions of interest related to vaccine targets (Table 2).

322

323 Antigen haplotypes lack geographic structure

324 To assess the genealogical relationships amongst sequence haplotypes obtained from our newly derived

325 Zambian sequences and those from other African countries, we used TCS network analysis for the ten

326 antigens. Full length genes, as well as known vaccine target regions, were examined and compared (Fig.

327 2 and 3). In general, haplotypes did not exhibit clustering, irrespective of vaccine antigen type and

328 geographic origin. This observation held true whether the analysis considered the entire gene or specific

329 functionally relevant domains, suggesting a lack of geographic structure. (Fig. 2 and 3).

330 We identified the following percent of unique haplotypes across all countries for individual full-length

331 genes: 41.2% (100/243) for CSP, 62.5% (362/579) for AMA1, 6.8% (28/413) for Rh5, 89.3% (175/196) for

332 MSP1, 0.9% (5/552) for Pfs25, 4.5% (24/539) for Pfs48/45, 89.1% (383/430) for Pfs230, 12.3% (64/522)

333 for *Pfs47*, 4.7% (25/531) for *Pfs28*, and 33.9% (190/560) for *CeITOS*. For certain genes, we examined

334 specific regions of interest related to vaccine targets and identified the following percent of unique

haplotypes across all countries: 17.2% (107/623) for CSP C-terminal, 52.8% (308/583) for AMA1

336 (Domains I-III), 2.8% (17/612) for MSP1 (C-terminal region: 19), 2.2% (12/562) for Pfs48/45 (C-terminal 6-

337 Cys domain), 24.5% (149/609) for *Pfs230* (N-terminal prodomain and Domains I-III), and 1.4% (8/555) for

338 *Pfs47* (Del2). We further separated unique haplotypes by country for each gene (see Table 2 for full

diversity statistics results breakdown). To contextualize this specifically for Zambia, when considering

340 unique haplotypes solely from this country, we observed a modest number across all genes: 44.3%

341 (31/70) for *CSP* full-length and 26.5% (18/68) for *CSP* partial, 20.6% (65/315) for *AMA1* full-length and

342 20.2% (50/248) for AMA1 partial, 18.8% (3/16) for Rh5 full-length, 29.5% (51/173) for MSP1 full-length

343 and 25% (1/4) for MSP1 partial, 33.3% (1/3) for Pfs25 full-length, 25% (4/16) for Pfs48/45 full-length and

344 28.6% (2/7) for *Pfs48/45* partial, 22.6% (86/381) for *Pfs230* full-length and 17.2% (20/116) for *Pfs230*

345 partial, 15.8% (6/38) for *Pfs47* full-length and 25% (1/4) for *Pfs47* partial, 23.8% (5/21) for *Pfs28* full-

346 length, and 24.4% (32/131) for *CeITOS* full-length. The 3D7 vaccine strain haplotype was dominant for

347 antigens Pfs48/45 (full-length and partial), and Pfs25 and Pfs28 (both full-length) (Fig. 3). In contrast, for

14

the more diverse antigens i.e., *Pfs230*, *AMA1*, *CSP* and *MSP1*, the 3D7 vaccine strain haplotype was
found at very low frequencies (Fig. 2 and 3).

350

351 Differing signals of selection, haplotype, and nucleotide diversity across antigen types for vaccine

352 development considerations

353 To understand haplotype diversity and investigate evidence of selection, we derived Nei's nucleotide 354 diversity (π), haplotype diversity (Hd) and *Tajima's* D statistics for each antigen. When taking full-length 355 genes into consideration, overall, five antigens, Pfs230, AMA1, CSP, MSP1, and CeITOS, representing 356 genes across the three categories of vaccine targets, exhibited the highest values of haplotype diversity 357 (Hd >0.9) across all parasite populations analyzed (Fig. 4a, Table 2). Two transmission-blocking antigens, 358 Pfs47 (0.85) and Pfs48/45 (0.73) showed a moderate-high level of haplotype diversity, with similar levels 359 as those demonstrated by the blood-stage antigen Rh5 (0.72) (Fig 4a, Table 2). The transmission-360 blocking antigen Pfs28 exhibited low haplotype diversity (0.29), and the lowest haplotype diversity was 361 observed for another transmission-blocking antigen, Pfs25 (0.03) (Fig. 4a, Table 2). When considering 362 antigens with specific regions of interest for vaccine development, the same trend was observed: AMA1, 363 CSP, and Pfs230 showed extremely high levels of haplotype diversity (0.99, 0.96, and 0.94, respectively), 364 followed by MSP1 with high haplotype diversity (0.77), while Pfs48/45 had moderate haplotype diversity 365 (0.43), and finally followed by *Pfs47* with the lowest haplotype diversity (0.35) (Fig. 4a, Table 2). 366 Furthermore, across the parasite populations, when examining all of the full-length genes, we detected 367 the highest levels of nucleotide diversity for CeITOS (0.0144) and AMA1 (0.0137) (Fig. 4b, Table 2). The 368 next highest levels of nucleotide diversity were shown for CSP (0.0067), MSP1 (0.0033), and this was 369 followed by similar levels observed for Pfs47 (0.0015), Pfs230 (0.0012), and Pfs48/45 (0.0011) (Fig. 4b, 370 Table 2). These values were tenfold higher than the nucleotide diversity observed for genes Rh5 and 371 Pfs28 (0.0009 and 0.0005, respectively, and one hundred-fold lower than the nucleotide diversity 372 observed for Pfs25 of 0.00001 (Fig. 4b, Table 2). When considering partial regions of interest for vaccine 373 development for the included genes, a similar pattern was observed; namely, CSP and AMA1 had the 374 highest nucleotide diversity (0.016 and 0.014, respectively), while MSP1, Pfs47, and Pfs230 had tenfold 375 lower nucleotide diversity (0.0057, 0.0024, and 0.0012), and Pfs48/45 had the lowest recorded nucleotide

15

376 diversity of 0.0011 among the genes for which partial regions were studied (Fig. 4b, Table 2). When 377 examining specimens from Zambia alone, haplotype and nucleotide diversity aligned with the observed 378 ranges in the parasite populations across the three categories of vaccine targets. 379 To assess SNP neutrality across genes, we conducted Tajima's D statistical test, comparing average 380 pairwise differences between samples and the total number of segregating sites (Fig. 4c, Table 2). 381 Tajima's D values of 0 indicate neutrality in constant-size populations, negative values suggest purifying 382 selection, and positive values suggest balancing selection. When examining full-length antigens, AMA1 383 showed the strongest signature of balancing selection, with CeITOS displaying neutrality and weaker 384 signs of balancing selection, CSP exhibiting neutrality with signs of purifying selection, and MSP1 385 similarly showing neutrality with signs of purifying selection (Fig. 4c, Table 2). Conversely, Pfs28, Pfs230, 386 Pfs47, Pfs25, Rh5, Pfs48/45 (in decreasing order) showed clear signatures of purifying selection (Fig. 4c, 387 Table 2). When inspecting antigens with partial regions of interest for vaccine development, we found that 388 AMA1 still demonstrated strong balancing selection, while MSP1 and CSP showed moderate signs of 389 balancing selection, contrasting with the full-length gene signatures (Fig. 4c, Table 2). On the other side 390 of the spectrum, Pfs230 and Pfs48/45 showed strong signs of purifying selection, while Pfs47 displayed 391 neutrality with moderate levels of purifying selection (Fig. 4c, Table 2). Overall, there was no clear 392 correlation between balancing selection signals with vaccine target type, although a general pattern was 393 observed with the sexual stage antigens mostly showing evidence of purifying selection.

394

395 Protein structures and balancing selection on known epitopes confirm transmission-blocking 396 antigens are not under immune selection

397 To facilitate the search for effective malaria vaccine targets, we applied three structure-based analyses to 398 the structures of ten vaccine candidate proteins (Table 1): nucleotide diversity of a focal residue's spatial 399 neighborhood (π^*). *Tajima's D* of a focal residue's spatial neighborhood (D^{*}), and summarization of 400 experimentally solved antibody-antigen structures (Fig. 5). We then explored if there was a high 401 concentration of sequence diversity and balancing selection signatures within certain domains or patches 402 of each protein. Additionally, we sought to determine if these regions correlated with known epitopes.

16

403 The 3D nucleotide diversity, π^* , of CSP, AMA1, CeITOS, and MSP1₁₉ showed the overall extreme 404 diversity of the molecules, which agrees with the 2D analysis. The 3D selection measure, D^* , however, 405 had greater variability across the molecules. CSP C-terminal domain exhibited uniformly high diversity and 406 selection, with 95% of spatial windows in regions of $\pi^* \ge 0.01$ (maximum $\pi^* = 0.046$), and 85% and 23% 407 of spatial windows under moderate to strong balancing $(D^* \ge 1)$ and strong balancing selection $(D^* \ge 2, 1)$ 408 maximum $D^* = 3.34$) respectively. The structurally characterized epitopes had similar diversity and 409 selection pressures as the full CSP C-terminal domain (Fig. S4). The D*, however, could be artificially 410 inflated for parts of the surface, including the conserved β -sheet epitope⁷⁴. Due to the small size of CSP 411 C-terminal domain, the 15Å spatial window implemented in biostructmap could include occluded residues 412 on the opposite surface with high polymorphism.

The known epitope of *AMA1*, structurally characterized from antibody 1F9⁷⁵ displayed higher diversity and stronger selection signature than the full *AMA1* structure. Overall, *AMA1* was found to have 58% of spatial windows in regions of $\pi^* \ge 0.01$ (maximum $\pi^* = 0.058$), and 67% were under moderate to strong balancing selection (maximum D* = 3.38), while the epitope of 1F9 shows 100% of their spatial windows in regions of high diversity and high selection. Additionally, we recovered the signature of *AMA1* displaying a distinctive side of the surface with heightened selection, and another side with no selection, termed the "silent face" of *AMA1*^{76,77} (Fig. 5).

420 *CeITOS* showed a distinctive region of low diversity and selection corresponding to its inferred 421 dimerization interface⁷⁸ (Fig. 5). The overall structure of *CeITOS* was found to have 66% of spatial 422 windows with $\pi^* \ge 0.01$ (maximum $\pi^* = 0.041$), and 55% of spatial windows under moderate to strong 423 balancing selection (maximum D* = 2.01) (Fig. S4).

424 *MSP1*₁₉, *Pfs48*/45, and *Rh5* contained regions under moderate balancing selection (D* between 1-2). 425 *MSP1*₁₉ domain 1 displayed stronger selection (mean D* = 0.67) than domain 2 (mean D* = 0.34). Among 426 the antibodies with characterized structures, 42D6 is the most potent and targets domains 1 and 2 at the 427 same time⁷⁹. One region in *Rh5* was found to be under selection, which is near its *Basigin* binding 428 interface⁸⁰. Interestingly, this region was shown to be targeted by infection-blocking antibodies⁸⁰⁻⁸². For 429 *Pfs48*/45, we found heightened diversity in domains 2 and 3 compared to domain 1, both of which are

17

430	binding sites of infection-blocking antibodies ⁸³ . Only part of domain 2 was found to be under moderate
431	balancing selection. Interestingly, none of the known epitopes overlap with the selected region.
432	Among the remaining four vaccine-candidate proteins encompassing the transmission-blocking
433	vaccine class, two had regions under weak balancing selection ($0 \le D^* < 1$): <i>Pfs230</i> (maximum $D^* = 0.66$)
434	and <i>Pfs47</i> (maximum $D^* = 0.75$), and two, <i>Pfs25</i> and <i>Pfs28</i> , were found to be entirely under purifying

436 **Discussion**

435

437 An ideal malaria vaccine target would be conserved with low balancing selection and containing

selection ($D^* \leq 0$) with maximum D^* of (-0.79) and (-0.78), respectively (Fig. S4).

438 infection/transmission blocking epitopes that induce strain-transcending antibodies. Against these criteria,

439 ten malaria vaccine antigens targeting sporozoite (n=1), merozoite (n=3) and sexual lifecycle stages

440 (n=6), were assessed against newly generated Zambian parasite genomes, together with publicly

441 available *P. falciparum* WGS spanning five other countries in Africa.

442 The frequency of unique haplotypes varied across merozoite antigens when considering their full 443 lengths, ranging from a high of 89.3% for MSP1 to a low of 6.8% for Rh5. Notably, transmission-blocking 444 antigens, including Pfs25, Pfs48/45, Pfs28, and Pfs47, exhibited markedly lower frequencies of unique 445 haplotypes (ranging from 0.9% to 12.3%) compared to the merozoite antigen AMA1 (62.5%) and the pre-446 erythrocytic antigen CSP (41.2%). Pfs230, another transmission-blocking antigen, demonstrated a 447 frequency of unique haplotypes similar to the highest recorded, MSP1 (88%). The high number of 448 haplotypes is expected due to the length of the protein (>3100 AAs and 14 domains) and many 449 haplotypes are the result of rare polymorphisms²⁵. CeITOS, another sexual stage antigen studied, 450 displayed a moderate frequency of unique haplotypes at 33.9%. When focusing on specific regions 451 targeted for vaccine development, the merozoite antigen AMA1 (Domains I-III) exhibited the highest 452 frequency of unique haplotypes (52.8%). In contrast, other antigens displayed lower frequencies: Pfs230 453 (N-terminal prodomain and Domains I-III) at 24.5%, CSP (C-terminal) at 17.2%, Pfs47 (Del2) at 6.1%, 454 MSP1 (C-terminal region: 19) at 2.8%, and Pfs48/45 (C-terminal 6-Cys domain) at 2.1%. These findings 455 suggest a lack of a strict pattern based on vaccine types, although transmission-blocking antigens

18

456 generally exhibited lower frequencies of unique haplotypes compared to other vaccine antigens.

457 Additionally, the observed low frequency unique haplotypes may be attributed to the high malaria458 transmission intensity in these regions of Africa.

459 Antibodies with varying effectiveness have been structurally characterized for seven of ten antigens 460 (see Table 1). Our genetic and structural analyses show that the human immune system plays an 461 important role in shaping the haplotype and nucleotide diversity of *P. falciparum* antigens, thus influencing 462 the potency and coverage of the antibodies. Based on the results, we identified five transmission-blocking 463 antigens (Pfs28, Pfs25, Pfs48/45, Pfs47, and Pfs230) and one blood-stage antigen (Rh5) as promising 464 candidates for developing broad-coverage vaccines. Pfs28 and Pfs25 demonstrate markedly lower 465 haplotype and nucleotide diversity than other antigens (Table 2; see also ^{40,84}) because they are not 466 expressed within human hosts and therefore they are not subjected to immune selection^{85,86}. The 467 drawback of no natural exposure to the human immune system from these two antigens is the lack of 468 antibody-boosting effect upon subsequent natural infections. Nevertheless, the low diversity and no signs 469 of selection warrant *Pfs28* and *Pfs25* as promising potential broad-coverage transmission blocking 470 vaccines. Additionally, combining antibodies raised to these antigens results in synergistic transmission 471 blocking activity, highlighting the possibility of a multi-component vaccine using Pfs25 and Pfs28⁸⁶. Other 472 transmission-blocking (sexual stage) antigens, such as Pfs48/45, Pfs47, and Pfs230, also represent 473 promising broad-coverage vaccine candidates, with the added advantage of antibody-boosting upon 474 subsequent exposure, and synergistic transmission blocking activity when combining antibodies of 475 Pfs48/45 and Pfs230⁸⁷. In addition, despite brief exposure to the immune system during merozoite 476 invasion⁸⁸, *Rh5* seems to be a more promising immunogen due to a less diverse haplotype population 477 and potent antibodies with cross-reactivity^{80,81}.

For the pre-erythrocytic antigen, *CSP* C-terminal domain was shown to be highly polymorphic in the current study [Fig. 5; see also ⁷⁴]. Notably, the 3D7 haplotype of *CSP* C-terminal domain represents only 3.7% of haplotypes circulating in our study (Fig. 2 and ²⁹). Earlier studies have shown that 3D7 haplotype-based RTS,S vaccine efficacy decreases with increased mutational distance from the 3D7 haplotype³³. *CSP* C-terminal domain has two characterized B-cell epitopes, and both are capable of weak inhibition of hepatocyte invasion⁷⁴. One overlaps with T-cell epitopes Th2R and Th3R and contains many

19

484 polymorphic residues, which limits the cross-reactivity of antibodies to other P. falciparum strains^{74,89}. A 485 second epitope on a conserved β-sheet of CSP C-terminal domain was shown to have broad cross-486 reactivity⁷⁴ but much weaker invasion inhibition than antibodies targeting NANP repeats^{74,90}. Overall, the 487 C-terminal domain of CSP might not be sufficient to elicit full protection for the entire parasite population, 488 namely in generating broad cross-reactive antibodies capable of potent inhibition of infection. 489 The blood-stage antigens, AMA1 (Domains I-III) and MSP119, are more diverse than the 490 transmission-blocking antigens, with a significant portion of their surface under at least moderate 491 balancing selection (Fig. 5). These results are consistent with previous studies investigating across Africa 492 and globally, with work revealing balancing selection and high haplotype diversity^{25,39,91}. Additionally, the 493 3D7 haplotype was not dominant for these antigens (Fig. 2). Many polymorphic residues in AMA1 1F9's 494 epitope found in our study were shown to abrogate 1F9 binding (H 200 [E,R,L,V], D 204 [K,N], I 225 495 [N])⁷⁵, implying that a single vaccine is unlikely to confer protection to multiple divergent haplotypes that 496 exist in natural parasite populations. Not included in the present structural analysis is a highly flexible loop 497 of D2, which has a conserved epitope (targeted by 4G2 monoclonal antibody⁹²). Among the antibodies 498 with characterized structures for MSP119, 42D6 is reported to be the most potent and targets domain 1 499 and 2 simultaneously⁷⁹. We found three polymorphic residues in the epitope of 42D6, two of which (Pf3D7 500 E1671K, L1692F) have been confirmed not to significantly impact binding, while the effect on binding and 501 potency of the third residue (Pf3D7 G1623R) remains uncharacterized and thus unknown. In contrast, 502 Rh5 is uniquely well-conserved among blood-stage antigens, as previously reported⁹³. Most potent 503 antibodies to Rh5 were found around the binding interface of Rh5 and human protein Basigin⁸¹. These 504 antibodies often target patches with no polymorphisms in our data with one exception (Pf3D7 C203Y), 505 which has been shown to not affect binding⁸¹. Other epitope regions near *Rh5*'s interface with *PfCyRPA* 506 were not effective in blocking merozoite invasion⁸². Therefore, targeting the *Rh5-Basigin* interface has the 507 potential as an effective vaccine against merozoite invasion. 508 For transmission-blocking antigens, Pfs47 was previously shown to be non-essential for P.

509 *falciparum* life cycle, as mutants lacking this protein were capable of normal fertilization⁹⁴. In contrast,

510 both *Pfs48/45* and *Pfs230* are essential antigens for *P. falciparum* life cycle^{95,96}. Potent transmission-

511 blocking antibodies have been characterized for *Pfs48/45*^{83,97,98}, *Pfs230 (D1, D2)*⁹⁹⁻¹⁰¹, and *Pfs47*¹⁰². As

20

512 reported above, we only found signals of weak or no balancing selection in these three antigens where 513 potent antibodies are binding. Polymorphic residues on domain 3 of Pfs48/45 in our dataset were found 514 not to affect binding affinity severely and the antibodies retained nanomolar affinity ranges⁹⁷. In Pfs230, 515 some of the potent transmission-blocking antibodies raised from natural exposure bound to regions with 516 no polymorphism in our study¹⁰⁰, while other potent antibodies raised from human vaccine trials bound to 517 polymorphic regions¹⁰¹. Among the polymorphic sites, (Pf3D7 G605S, D714N) were shown to affect 518 binding, while (Pf3D7 E654K, E655V, and A699T) did not. The remaining set of polymorphic residues 519 (Pf3D7 N616K, T656N, V727I) segregate at low frequencies and have not been tested for changes in 520 binding affinities. Pfs47 also contained polymorphic residues in the epitope of a potent antibody¹⁰². 521 However, the influence of these polymorphisms has not been characterized. Immunization to both Pfs28 522 and Pfs25 have been shown to raise potent transmission-blocking antibodies^{86,103-112}. The impact of 523 polymorphic residues (Pf3D7 L63V, V132I) of Pfs25 on the binding affinities of the antibodies has not yet 524 been characterized. 525 While a part of transmission-blocking antigens, CeITOS is critical to liver invasion by sporozoites 526 during the pre-erythrocytic stage⁷⁸. The heightened balancing selection pressure and nucleotide diversity 527 of CeITOS compared to the other transmission-blocking target antigens reflects its intense interaction with 528 the human immune system. While no antibodies have been structurally characterized against CeITOS at 529 the time of this study, it has been shown that mice immunized with CeITOS can raise potent transmission-530 blocking antibodies¹¹³. However, with nearly the entire surface exposed regions of CeITOS under 531 moderate balancing selection, it is unlikely to provide broad-coverage vaccinations. 532 We acknowledge that this study is not without limitations. Firstly, it was a secondary analysis of a 533 broader study⁴³, and we did not intend to do an exhaustive study of all vaccine candidate genes. We 534 chose to incorporate representative genes across the three classes of vaccine candidates with a focus on

535 transmission-blocking antigens that are currently under clinical vaccine development. Identifying potential

536 vaccine targets from the proteome is beyond our study scope. Secondly, our study used samples mainly

537 from sub-Saharan Africa with a particular focus on Zambia where genomic data were lacking. However,

538 we acknowledge the absence of representation from Asia or South America. While we recognize that a

539 study with a globally representative set of samples would be more comprehensive, we believe that this

21

540	investigation is still useful for understanding vaccine development in the context of Africa and Zambia
541	specifically, a country that remains highly malaria endemic. Lastly, the analyses of full-length and partial
542	genes should not be directly compared as they incorporated varying numbers of samples (the partial
543	genes typically included more samples than the full-length genes). The partial gene analyses for regions
544	of interest and the corresponding 3D structural analyses are more relevant for informing vaccine
545	development.
546	In conclusion, this study offers valuable insights into selecting P. falciparum vaccine antigens with regions
547	under low balancing selection and the presence of infection/transmission-blocking epitopes, which are
548	essential for informing the development of new malaria vaccines. Based on these findings, we
549	recommend the following strategies for vaccine design: 1) a multi-stage vaccine encompassing anti-
550	merozoite (Rh5) and transmission-blocking antigens (Pfs25, Pfs28, Pfs48/45, Pfs230), and 2)
551	transmission-blocking vaccines targeting combinations of Pfs25, Pfs28, and Pfs48/45. These approaches
552	hold promise for the development of more effective malaria vaccines in the future.
553	
554	Contributors
555	I.I.C, Q.H. and G.C. conceived and designed the study. I.I.C, B.K.B, S.X., Q.H and G.C. generated and
556	collected data. S.X., I.I.C., B.K.B., Q.H., and G.C. analyzed data and interpret results. J.T., Q.H. and G.C.
557	supervised analysis. M.C.M., B.M., C.M., J.M., J.L.S. W.J.M., and D.J.B. contributed to
558	samples/materials. I.I.C., B.K.B., Q.H., and G.C wrote the manuscript. All authors read, edited, and
559	approved the manuscript for publication.
560	

561 **Declaration of interests**

562 All authors declare no competing interests.

563

564 Data Sharing

565	The raw sequence data are available in the NCBI Sequence Read Archive under BioProject
566	PRJNA932927. Key analysis scripts can be accessed at https://github.com/giocarpi/Pf_capture_div_code
567	
568	Acknowledgements
569	We would like to thank collaborators at the Zambia National Malaria Elimination Centre, the study
570	participants, and the Southern and Central Africa International Centers of Excellence for Malaria
571	Research (ICEMR). We would also like to extend our gratitude to the communities and researchers of
572	malaria endemic countries that enabled the collection and availability of the P. falciparum genomes used
573	in this study and made publicly available through the MalariaGEN P. falciparum Community. The authors
574	would also like to thank Abebe Fola for his contributions in extracting genomic DNA from DBS samples.
575	
576	Additional information
577	Correspondence should be addressed to Giovanna Carpi and Qixin He.
578 579	
580	
581	
582	
583	
584	
501	
585	
586	
587	
588	
589	
590	

23

591 Figures and Tables



592

593 Figure 1. *Plasmodium falciparum* life cycle in the *Anopheles* mosquito vector and human host and 594 corresponding targets for malaria vaccine development.

595 Vaccine strategies are broadly grouped by the P. falciparum life stage they target and include the 596 categories: pre-erythrocytic, blood stage, and transmission-blocking. The pre-erythrocytic class of 597 vaccines usually include candidates that target sporozoites or infected hepatocytes to prevent clinical 598 initial infection and stop malaria parasites from re-entering the bloodstream. The blood stage vaccines 599 target the parasite during replication in red blood cells in the human. Lastly, transmission-blocking 600 vaccines target sexual and/or sporogonic development stages and aim to induce antibodies in humans 601 that impair the parasite's development inside the mosquito midgut and thus subsequently prevent the 602 transmission of sporozoites to humans. The antigens shown in bold were included in this study.



605 Figure 2. Haplotype network for malaria vaccine antigens (pre-erythrocytic and blood-stage

- 606 **proteins).** Templeton, Crandall, and Sing (TCS) networks illustrate the diversity of the selected antigens.
- 607 Circles represent unique nucleotide haplotypes and are scaled according to the frequency with which the
- 608 haplotype was observed. The number of mutation differences that exist between each haplotype is
- 609 depicted by the number of hatch marks on the network branches. Haplotype colors match the geographic
- 610 origin of the samples depicted on the map (see map legend). The vaccine strain 3D7 (grey color,
- 611 surrounded by a red box) is included for reference in each respective haplotype network.
- 612



615	Figure 3. Haplotype n	etwork for malaria v	accine antigens	(transmission-blocking proteins).
				(

- 616 Templeton, Crandall, and Sing (TCS) networks illustrate the diversity of the selected antigens. Circles
- 617 represent unique nucleotide haplotypes and are scaled according to the frequency with which the
- 618 haplotype was observed. The number of mutation differences that exist between each haplotype is
- 619 depicted by the number of hatch marks on the network branches. Haplotype colors match the geographic
- 620 origin of the samples depicted on the map (see map legend). The vaccine strain 3D7 (grey color,
- 621 surrounded by a red box) is included for reference in each respective haplotype network.
- 622
- 623
- 624
- 625
- 0_0
- 626 627
- 0_.
- 628
- 629
- 630
- 631
- 632
- 633

634

- _
- 636
- 637

medRxiv preprint doi: https://doi.org/10.1101/2024.05.11.24307175; this version posted May 12, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.





639 Figure 4. Results of haplotype diversity, nucleotide diversity, and Tajima's D values for each 640 antigen across all countries included in this study. The horizontal barplot depicts the calculated 641 values for the specified diversity parameters for each antigen across the different parasite populations. 642 Three diversity parameters were included: haplotype diversity (panel a) and nucleotide diversity (panel b) 643 (calculated using DNAsp), and Tajima's D statistic (panel c) (calculated using MEGA). Colors are selected 644 to show the lifecycle stage of the parasite of the respective antigen (see legend for specific colors) and 645 also correspond to the colors depicted in Fig. 1 of the *P. falciparum* parasite life cycle stages. The fully 646 shaded-in bars indicate full-length genes, while the dashed bars denote partial length genes for genes 647 with specific regions of interest for vaccine development. 648

649

650



653

654 Figure 5. Vaccine candidate structural analyses of nucleotide diversity (π^*), Tajima's D*, and 655 antibody-antigen interactions (epitopes). A 3D sliding window of 15 Å was used for all calculations. 656 Residues with no nearby SNP mapping residues are colored grey. Nucleotide diversity (π^*) uses a log 657 scale from extremely low diversity (10⁻⁵) to extremely high diversity (10⁻¹). Tajima's D* varies from no 658 balancing selection (<0) to strong balancing selection (>2) on a linear scale. In the column of known 659 epitopes, the discrete color scale indicates the number of times a residue was part of an antibody-antigen 660 structure deposited in RCSB. This column is additionally annotated with relevant domain, epitope, and 661 protein-protein interaction surfaces.

30

Table 1. Vaccine candidate antigens.

- 663 *P. falciparum* antigens included in this study, with respective type of vaccine, lifecycle stage, full or partial
- gene used in analyses from NCBI gene database, and 3-D structure reference and antibody-antigen
- 665 structures used in analyses from Research Collaboratory for Structural Bioinformatics (RCSB) database.
- 666 The gene information of the proteins is provided in Table S1. All are relevant key candidates from malaria
- vaccine trials and are functionally important for malaria biology as they target different stages of the
- 668 Plasmodium falciparum life cycle (See Figure 1). AF2 represents AlphaFold solved structures. "---"
- 669 indicates we used AlphaFold to resolve loop regions instead of the solved structure (see Methods for
- 670 details).
- 671

Type of vaccine	Protein Analysis (full/		Structure	AA start -	Antibody-Antigen structures
(Parasite lifecycle	Name	partial gene), [nt]	reference	AA end	
stage)					
Pre-erythrocytic (sporozoite)	CSP	full-length, partial (C-terminal), [829-1194]	7rxp (⁷⁴)	309 – 373	6b0s (⁸⁹), [7rxi, 7rxj, 7rxl, 7rxp, 7s0x] (⁷⁴)
	AMA1	partial (Domains I-III), [298-1635]	2q8a (⁷⁵)	107 – 438	[2q8a, 2q8b] (⁷⁵)
Blood-stage	Rh5	full-length	4wat (¹¹⁴)	146 – 513	[4u0r, 4u1g] (⁸⁰), 5mi0 (¹¹⁵), [6rcu,
(merozoite)					6rcv] (⁶¹), [/pnu] (⁶²)
	MSP1	partial (C-terminal	8dfh> AF2	1608 -	[8dfh, 8dfi, 8dfg] (⁷⁹), 1ob1 (¹¹⁶),
		region: 19),		1699	6xqw (¹¹⁷)
		[4822-5097]			
Transmission-blocking (sexual and/or	Pfs25	full-length	6b0e (¹⁰⁷) → AF2	23 – 193	[6azz, 6b0h, 6b0e, 6b08, 6b0a, 6b0g] (¹⁰⁷), [6phb, 6phd, 6phf, 6phc] (¹⁰⁸), 7txw (¹¹⁸)

			_	_	_
sporogonic	Pfs48/45	full-length, partial (C-	$7zxg (^{83}) \rightarrow AF2$	45 – 428	[7zwf, 7zwi, 7zxf, 7zwm, 7zxg] (⁸³),
development stages)		terminal 6-Cys			6h5n (⁸³), 7uxl (⁹⁷), 7unb (¹¹⁹), [6e63,
		domain),			6e62] (¹²⁰)
		[871-1284]			
	Pfs230	full-length, partial	7ufw (¹⁰¹) \rightarrow AF2	552 - 890	6ohg (⁸⁷), 7jum (⁹⁹), [7uvi, 7uvq,
		(N-terminal			7uvs, 7uvo, 7uvh] (¹⁰⁰), [7u9w, 7ua2,
		prodomain +			7ufw,7ua8, 7ubs, 7ucq, 7uc8, 7u9e,
		Domains I-III),			7ui1] (¹⁰¹)
		[1327-3396]			
	Pfs47	full-length, partial	None → AF2	22 – 419	Linear epitope (no structure solved)
		(Del2),			for amino acids 178-229 (102)
		[532-687]			
	Pfs28	full-length	8e1z (¹²¹)	24 - 178	N/A
		full longth	(Du) Etcz (78)	25 164	N1/A
	Cerros	Tui-length	(FV) 5152 (**)>	55 - 164	N/A
			AFZ		
672 673					
674					
675					
676					
677					
678					
679					
680					
681					
682					
683					
684					

32

685 **Table 2. Diversity Statistics Results.**

- 686 Summary of the samples from Africa included in our analyses per gene.
- 687 n=number of sequences, h=number of unique haplotypes, hc=number of unique haplotypes from a
- 688 respective country alone, S=number of polymorphic (segregating) sites, k=average number of pairwise
- 689 nucleotide differences, Hd=haplotype (gene) diversity, π=nucleotide diversity, *D*=Tajima's neutrality test
- 690 statistic

Gene Name	Country	n	h	h _c	S	k	Hd	π	D
(Gene Symbol)									
(PF3D7_0304600)	All	243	100	70	63	7.321	0.977	0.0067	-0.877
CSP, full	DRC	25	17	7	33	8.140	0.923	0.0070	-0.258
	Ghana	51	34	12	30	6.921	0.976	0.0059	0.126
	Guinea	41	23	7	28	6.667	0.951	0.0058	0.064
	Malawi	32	18	4	29	7.486	0.958	0.0065	0.141
	Tanzania	20	16	9	27	7.147	0.974	0.0061	-0.237
	Zambia	74	50	31	50	8.061	0.985	0.0072	-0.703
(PF3D7_0304600)	All	623	107	68	38	5.987	0.962	0.0164	0.277
CSP, partial	DRC	73	27	6	23	5.960	0.946	0.0163	0.797
(C-terminal)	Ghana	138	44	18	28	5.685	0.953	0.0156	0.341
	Guinea	72	29	6	23	6.079	0.957	0.0166	0.865
	Malawi	125	40	12	26	5.757	0.964	0.0157	0.572
	Tanzania	50	23	8	24	5.783	0.951	0.0158	0.258
	Zambia	165	45	18	26	6.322	0.952	0.0173	1.080
(PF3D7_1133400)	All	579	362	315	114	25.550	0.997	0.0137	1.606
AMA1, full	DRC	70	60	50	82	25.598	0.993	0.0137	1.710
	Ghana	129	99	79	88	25.124	0.993	0.0134	1.762
	Guinea	71	60	45	85	24.690	0.992	0.0132	1.369
	Malawi	125	73	51	84	25.762	0.990	0.0138	2.101
	Tanzania	52	43	25	76	25.519	0.991	0.0137	1.812
	Zambia	132	89	65	87	25.635	0.987	0.0137	1.938
	All	583	308	248	84	21.319	0.995	0.0159	2.171

	DRC	71	54	36	64	21.384	0.985	0.0160	2.059
(PF3D7_1133400) Ghana	131	89	63	68	20.715	0.991	0.0155	2.080
AMA1, partial	Guinea	71	59	39	70	21.041	0.992	0.0157	1.522
(Domains I-III)	Malawi	125	69	39	66	21.477	0.989	0.0161	2.395
	Tanzania	52	43	21	61	21.548	0.991	0.0161	2.069
	Zambia	133	82	50	70	21.454	0.985	0.0160	2.127
(PF3D7_042410	0) <i>All</i>	413	28	16	19	1.347	0.718	0.0009	-1.318
Rh5, full	DRC	28	7	2	7	1.013	0.624	0.0006	-1.312
	Ghana	112	12	4	9	0.692	0.530	0.0004	-1.456
	Guinea	66	9	0	6	0.814	0.616	0.0005	-0.854
	Malawi	116	10	1	7	1.637	0.785	0.0010	0.562
	Tanzania	41	14	6	11	1.715	0.790	0.0011	-1.006
	Zambia	50	11	3	9	1.312	0.682	0.0008	-0.972
(PF3D7_093030	0) <i>All</i>	196	175	173	118	16.510	0.999	0.0033	-0.565
MSP1, full	DRC	20	18	17	61	17.100	0.989	0.0034	-0.022
	Ghana	37	35	35	81	16.480	0.997	0.0033	-0.554
	Guinea	22	22	22	67	17.403	1.000	0.0035	-0.212
	Malawi	52	40	39	67	15.778	0.989	0.0031	0.223
	Tanzania	10	10	9	49	15.467	1.000	0.0031	-0.523
	Zambia	55	52	51	71	15.727	0.998	0.0031	0.047
(PF3D7_093030	0) <i>All</i>	612	17	4	8	1.585	0.773	0.0057	0.752
MSP1, partial	DRC	73	11	0	7	1.648	0.800	0.0060	0.357
(C-terminal regio	n: Ghana	139	9	0	6	1.571	0.729	0.0057	0.944
19)	Guinea	73	11	1	8	1.801	0.791	0.0065	0.241
	Malawi	124	12	1	7	1.613	0.782	0.0058	0.551
	Tanzania	49	9	1	7	1.480	0.751	0.0054	-0.153
	Zambia	154	11	1	7	1.436	0.764	0.0052	0.333
(PF3D7_103100	0) <i>All</i>	552	5	3	4	0.029	0.029	0.0000	-1.489
<i>Pfs</i> 25, full	DRC	67	1	0	0	0.000	0.000	0.0000	n/c
	Ghana	128	1	0	0	0.000	0.000	0.0000	n/c
	Guinea	67	1	0	0	0.000	0.000	0.0000	n/c
	Malawi	121	4	2	3	0.082	0.081	0.0001	-1.480
	Tanzania	47	2	0	1	0.043	0.043	0.0000	-1.109
1	L		1		L	1			

1						•			
	Zambia	122	3	1	2	0.033	0.033	0.0001	-1.351
(PF3D7_1346700)	All	539	24	16	19	1.433	0.734	0.0011	-1.168
<i>P</i> fs48/45, full	DRC	65	9	3	6	1.242	0.648	0.0009	-0.043
	Ghana	128	13	6	9	1.151	0.691	0.0009	-0.738
	Guinea	65	8	2	6	0.912	0.633	0.0007	-0.676
	Malawi	117	8	1	6	1.394	0.668	0.0010	0.525
	Tanzania	49	6	0	3	1.350	0.687	0.0010	2.090
	Zambia	115	12	4	8	1.205	0.671	0.0009	-0.473
(PF3D7_1346700)	All	562	12	7	11	0.452	0.429	0.0011	-1.534
Pfs48/45, partial	DRC	57	4	1	3	0.200	0.195	0.0005	-1.322
(C-terminal 6-Cys	Ghana	131	4	1	3	0.564	0.525	0.0014	0.042
domain)	Guinea	67	5	2	4	0.594	0.544	0.0014	-0.621
	Malawi	118	4	1	3	0.299	0.292	0.0007	-0.814
	Tanzania	49	2	0	1	0.332	0.332	0.0008	0.647
	Zambia	130	7	2	6	0.225	0.215	0.0005	-1.718
(PF3D7_0209000)	All	430	383	381	180	11.082	0.999	0.0012	-1.771
<i>Pfs230</i> , full	DRC	50	47	47	64	11.440	0.998	0.0012	-0.697
	Ghana	85	83	83	89	11.085	0.999	0.0012	-1.251
	Guinea	57	55	54	72	10.936	0.999	0.0012	-1.035
	Malawi	103	77	75	75	9.224	0.995	0.0010	-1.166
	Tanzania	37	37	36	46	9.216	1.000	0.0010	-0.587
	Zambia	98	87	86	68	9.389	0.995	0.0010	-0.934
(PF3D7_0209000)	All	609	149	116	53	2.452	0.944	0.0012	-1.859
<i>Pfs230</i> , partial	DRC	68	34	15	23	2.575	0.953	0.0013	-1.438
(N-terminal	Ghana	134	64	39	29	2.897	0.963	0.0014	-1.330
prodomain +	Guinea	74	38	21	18	2.702	0.964	0.0013	-0.796
Domains I-III)	Malawi	129	37	11	18	2.079	0.916	0.0010	-1.029
	Tanzania	49	22	10	17	2.148	0.923	0.0010	-1.368
	Zambia	155	40	20	21	2.155	0.919	0.0011	-1.173
(PF3D7_1346800)	All	522	64	38	33	2.022	0.850	0.0015	-1.536
Pfs47, full	DRC	60	20	6	12	2.267	0.925	0.0017	-0.341
	Ghana	124	30	13	19	1.982	0.808	0.0015	-1.224
	Guinea	67	16	3	10	1.663	0.772	0.0013	-0.561

	Malawi	118	25	8	16	1.468	0.652	0.0011	-1.396
	Tanzania	46	14	2	11	1.837	0.812	0.0014	-0.787
	Zambia	107	22	6	13	1.623	0.741	0.0012	-0.922
(PF3D7_1346800)	All	555	8	4	7	0.380	0.354	0.0024	-1.184
Pfs47, partial	DRC	66	4	0	3	0.626	0.565	0.0040	-0.015
(Del2)	Ghana	132	5	1	4	0.461	0.419	0.0030	-0.703
	Guinea	69	5	1	4	0.394	0.370	0.0025	-1.119
	Malawi	121	5	1	4	0.160	0.142	0.0010	-1.509
	Tanzania	49	4	0	3	0.347	0.327	0.0022	-1.005
	Zambia	118	4	1	3	0.295	0.289	0.0019	-0.828
(PF3D7_1030900)	All	531	25	21	23	0.313	0.291	0.0005	-2.272
<i>Pf</i> s28, full	DRC	62	3	1	2	0.236	0.232	0.0004	-0.757
	Ghana	125	7	5	6	0.340	0.326	0.0005	-1.506
	Guinea	66	6	3	5	0.314	0.298	0.0005	-1.608
	Malawi	119	10	6	9	0.280	0.263	0.0004	-2.028
	Tanzania	46	5	1	4	0.215	0.207	0.0003	-1.764
	Zambia	113	8	5	7	0.386	0.338	0.0006	-1.628
(PF3D7_1216600)	All	560	190	131	42	7.891	0.981	0.0144	0.803
CeITOS, full	DRC	68	40	15	28	7.026	0.965	0.0128	0.639
	Ghana	131	70	38	29	8.331	0.979	0.0152	1.663
	Guinea	66	42	13	28	7.998	0.973	0.0146	1.138
	Malawi	122	55	25	30	7.848	0.974	0.0143	1.210
	Tanzania	49	33	8	30	7.571	0.969	0.0138	0.418
	Zambia	124	65	32	37	7.659	0.978	0.0140	0.353

36

696 Supplementary Material



- Figure S1. Map of African endemic countries from which *P. falciparum* WGS were included in the
 study. Map showing the newly generated *P. falciparum* WGS from Zambia (outlined in black) and publicly
 available WGS data from other malaria endemic countries (MalariaGEN Pf3K) (shown in dark grey).
- 701
- 702
- 703
- 704



705

706 Figure S2. Characterization of multiplicity of infections estimated by *Fws* among 1092 *P*.

707 *falciparum* genomes across 6 African countries. Colored bars represent the proportion of samples

with different levels of multiplicity of infection in each country based on *Fws*. MOI=1: *Fws* above 0.95;

709 MOI=2, *Fws* between 0.8 and 0.95; MOI>2, *Fws* below 0.8.

710



Figure S3. Vaccine candidates' AlphaFold2 model confidence. The color scale represents
AlphaFold2's reported predicted local Distance Difference Test (pLDDT) for each structure model. See
methods for AlphaFold2 implementation. Text under protein names indicates reference structure models
and the agreement of alignments measured in Root Mean Squared Deviation (RMSD) over a certain
number of atoms.

39



722 Figure S4. Spatially derived nucleotide diversity and Tajima's D summaries for whole protein 723 structures versus known epitope residues. Known epitope residues, indicated as "epi: protein name", 724 are calculated from solved antibody-antigen structures listed in Table 1. Color indicates the proportion of 725 residues in each corresponding bin of nucleotide diversity. See methods for calculation of spatially 726 derived statistics and calculation of epitope residues from solved structures. A) Summary of spatially 727 derived nucleotide diversity (π^*) values for whole protein structures versus known epitope residues. B) 728 Summary of spatially derived Tajima's D (D*) values for whole protein structures versus known epitope 729 residues. 730

731

721

40

733 Table S1. Gene information of vaccine candidate antigens.

- 734 Chromosome number and coordinates, relevant gene symbol and IDs of *P. falciparum* antigens from
- 735 NCBI gene database.

Gene Name	Chromosome	Chromosome	Gene Symbol	Gene ID
	Number	Coordinates		
CSP	3	(221323222516, complement)	PF3D7_0304600	814364
AMA1	11	(12938561295724)	PF3D7_1133400	810891
RH5	4	(10823631084150, complement)	PF3D7_0424100	812437
MSP1	9	(12018121206974)	PF3D7_0930300	813575
Pfs25	10	(12534171254070, complement)	PF3D7_1031000	810560
Pfs45/48	13	(18760161877362, complement)	PF3D7_1346700	814212
Pfs230	2	(370438379845)	PF3D7_0209000	812682
Pfs47	13	(18788751880194, complement)	PF3D7_1346800	814213
Pfs28	10	(12511511251807, complement)	PF3D7_1030900	810459
CeITOS	12	(659738660286, complement)	PF3D7_1216600	811213

736

41

738 **References**

739

740 Duffy PE, Sahu T, Akue A, Milman N, Anderson C. Pre-erythrocytic malaria vaccines: 1. 741 identifying the targets. Expert Review of Vaccines 2012; 11(10): 1261-80. 742 Marques-da-Silva C, Peissig K, Kurup SP. Pre-Erythrocytic Vaccines against Malaria. 2. 743 Vaccines 2020; 8(3): 400. 744 3. Duffy PE, Patrick Gorres J. Malaria vaccines since 2000: progress, priorities, products. 745 npj Vaccines 2020; 5(1): 48. 746 Molina-Franky J, Cuy-Chaparro L, Camargo A, et al. Plasmodium falciparum pre-4. 747 erythrocytic stage vaccine development. Malaria Journal 2020; 19(1): 56. 748 WHO. WHO recommends groundbreaking malaria vaccine for children at risk. 2021. 5. 749 https://www.who.int/news/item/06-10-2021-who-recommends-groundbreaking-malaria-vaccine-750 for-children-at-risk (accessed February 11 2023). 751 Oxford. Oxford R21/Matrix-MTM malaria vaccine receives regulatory clearance for use in 6. 752 Burkina Faso. 2023. https://www.ox.ac.uk/news/2023-07-24-oxford-r21matrix-m-malaria-753 vaccine-receives-regulatory-clearance-use-burkina-faso (accessed September 9 2023). 754 Friedman-Klabanoff DJ, Berry AA, Travassos MA, et al. Low dose recombinant full-7. 755 length circumsporozoite protein-based Plasmodium falciparum vaccine is well-tolerated and 756 highly immunogenic in phase 1 first-in-human clinical testing. Vaccine 2021; **39**(8): 1195-200. 757 8. Miura K. Progress and prospects for blood-stage malaria vaccines. Expert Review of 758 Vaccines 2016; 15(6): 765-81. 759 Sauerwein RW, Bousema T. Transmission blocking malaria vaccines: Assays and 9. 760 candidates in clinical development. Vaccine 2015; 33(52): 7476-82. 761 Coelho CH, Rappuoli R, Hotez PJ, Duffy PE, Transmission-Blocking Vaccines for 10. 762 Malaria: Time to Talk about Vaccine Introduction. Trends in Parasitology 2019; 35(7): 483-6. 763 11. WHO. World malaria report 2022. 2022. 764 https://www.who.int/publications/i/item/9789240064898 (accessed February 9 2023). Laurens MB. RTS, S/AS01 vaccine (MosquirixTM): an overview. *Hum Vaccin* 765 12. 766 Immunother 2020; 16(3): 480-9. 767 Keating C. The history of the RTS,S/AS01 malaria vaccine trial. The Lancet 2020; 13. 768 **395**(10233): 1336-7. 769 WHO. WHO review of malaria vaccine clinical development. 2024. 14. 770 https://www.who.int/observatories/global-observatory-on-health-research-and-771 development/monitoring/who-review-of-malaria-vaccine-clinical-development (accessed 772 February 15 2024). 773 Oxford. Oxford R21/Matrix-MTM malaria vaccine receives WHO recommendation for 15. 774 use paving the way for global roll-out. 2023. https://www.ox.ac.uk/news/2023-10-02-oxford-775 r21matrix-m-malaria-vaccine-receives-who-recommendation-use-paving-way-global (accessed 776 February 9 2024). 777 Gardner MJ, Hall N, Fung E, et al. Genome sequence of the human malaria parasite 16. 778 Plasmodium falciparum. Nature 2002; 419(6906): 498-511. 779 17. Cockburn IA, Seder RA. Malaria prevention: from immunological concepts to effective 780 vaccines and protective antibodies. *Nature Immunology* 2018; **19**(11): 1199-211. 781 Kirchner S, Power BJ, Waters AP. Recent advances in malaria genomics and 18. 782 epigenomics. Genome Medicine 2016; 8(1): 92.

42

783	19. Bonam SR, Rénia L, Tadepalli G, Bayry J, Kumar HMS. Plasmodium falciparum
784	Malaria Vaccines and Vaccine Adjuvants. Vaccines 2021; 9(10): 1072.
785	20. Coppel RL. Vaccinating with the genome: a Sisyphean task? <i>Trends in Parasitology</i>
786	2009; 25 (5): 205-12.
787	21. Pandey I, Quadiri A, Wadi I, Pillai CR, Singh AP, Das A. Conserved Plasmodium
788	Protein (PF3D7_0406000) of Unknown Function: In-silico Analysis and Cellular Localization.
789	Infection, Genetics and Evolution 2021; 92: 104848.
790	22. Mu J, Awadalla P, Duan J, et al. Genome-wide variation and identification of vaccine
791	targets in the Plasmodium falciparum genome. <i>Nature Genetics</i> 2007; 39 (1): 126-30.
792	23. Goodswen SJ, Kennedy PJ, Ellis JT. A guide to current methodology and usage of
793	reverse vaccinology towards in silico vaccine discovery. FEMS Microbiology Reviews 2023;
794	47 (2).
795	24. Beeson JG, Kurtovic L, Dobaño C, et al. Challenges and strategies for developing
796	efficacious and long-lasting malaria vaccines. Science Translational Medicine 2019; 11(474):
797	eaau1458.
798	25. Naung MT, Martin E, Munro J, et al. Global diversity and balancing selection of 23
799	leading Plasmodium falciparum candidate vaccine antigens. PLOS Computational Biology 2022;
800	18 (2): e1009801.
801	26. Olotu A, Fegan G, Wambua J, et al. Seven-Year Efficacy of RTS,S/AS01 Malaria
802	Vaccine among Young African Children. New England Journal of Medicine 2016; 374(26):
803	2519-29.
804	27. CTP. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose
805	in infants and children in Africa: final results of a phase 3, individually randomised, controlled
806	trial. The Lancet 2015; 386 (9988): 31-45.
807	28. de Vrieze J. First malaria vaccine rolled out in Africa—despite limited efficacy and
808	nagging safety concerns. 2019. https://www.science.org/content/article/first-malaria-vaccine-
809	rolled-out-africa-despite-limited-efficacy-and-nagging-safety.
810	29. Pringle JC, Carpi G, Almagro-Garcia J, et al. RTS, S/AS01 malaria vaccine mismatch
811	observed among Plasmodium falciparum isolates from southern and central Africa and globally.
812	Scientific Reports 2018; 8(1): 6622.
813	30. Bell GJ, Agnandji ST, Asante KP, et al. Impacts of Ecology, Parasite Antigenic
814	Variation, and Human Genetics on RTS,S/AS01e Malaria Vaccine Efficacy. Current
815	<i>Epidemiology Reports</i> 2021; 8 (3): 79-88.
816	31. Preston MD, Campino S, Assefa SA, et al. A barcode of organellar genome
817	polymorphisms identifies the geographic origin of Plasmodium falciparum strains. Nature
818	<i>Communications</i> 2014; 5 (1): 4052.
819	32. Bailey JA, Mvalo T, Aragam N, et al. Use of Massively Parallel Pyrosequencing to
820	Evaluate the Diversity of and Selection on Plasmodium falciparum csp T-Cell Epitopes in
821	Lilongwe, Malawi. The Journal of Infectious Diseases 2012; 206(4): 580-7.
822	33. Neafsey DE, Juraska M, Bedford T, et al. Genetic Diversity and Protective Efficacy of
823	the RTS,S/AS01 Malaria Vaccine. New England Journal of Medicine 2015; 373(21): 2025-37.
824	34. Mangou K, Moore AJ, Thiam LG, et al. Structure-guided insights into potential function
825	of novel genetic variants in the malaria vaccine candidate PfRh5. Scientific Reports 2022; 12(1):
826	19403.

35. Zhang H, Wang L, Compans RW, Wang B-Z. Universal Influenza Vaccines, a Dream to
Be Realized Soon. *Viruses* 2014; 6(5): 1974-91.

829	36. Bullard BL, Weaver EA. Strategies Targeting Hemagglutinin as a Universal Influenza
830	vaccine. <i>vaccines</i> 2021; 9(3): 257.
022	57. Giuliani Mivi, Adu-Boble J, Colhanducci M, et al. A universal vaccine for serogroup B
832	meningococcus. Proceedings of the National Academy of Sciences 2006; 103 (29): 10834-9.
833	38. Some AF, Bazie I, Zongo I, et al. Plasmodium falciparum msp1 and msp2 genetic
834	diversity and allele frequencies in parasites isolated from symptomatic malaria patients in Bobo-
835	Dioulasso, Burkina Faso. Parasites & Vectors 2018; 11 (1): 323.
836	39. Nirmolia I, Ahmed MA, Sathishkumar V, et al. Genetic diversity of Plasmodium
837	falciparum AMA-1 antigen from the Northeast Indian state of Tripura and comparison with
838	global sequences: implications for vaccine development. <i>Malaria Journal</i> 2022; 21 (1): 62.
839	40. Sookpongthai P, Utayopas K, Sitthiyotha T, et al. Global diversity of the gene encoding
840	the Pfs25 protein—a Plasmodium falciparum transmission-blocking vaccine candidate. <i>Parasites</i>
841	& Vectors 2021; 14 (1): 571.
842	41. Ouattara A, Dwivedi A, Adams M, et al. An In Silico Analysis of Malaria Pre-
843 844	Erythrocytic-Stage Antigens Interpreting Worldwide Genetic Data to Suggest Vaccine Candidate Variants and Epitopes. <i>Microorganisms</i> 2022; 10 (6): 1090.
845	42. WHO. World malaria report 2023, 2023, https://www.who.int/teams/global-malaria-
846	programme/reports/world-malaria-report-2023 (accessed February 3 2024)
847	43 Fola AA, He O, Xie S, et al. Genomics reveals heterogeneous Plasmodium falcinarum
848	transmission and selection signals in Zambia Communications Medicine 2024: 4(1): 67
849	44. Ministry of Health Zambia M. Zambia National Malaria Indicator Survey Report, 2015
850	2019 https://www.path.org/resources/zambia-natl-malaria-indicator-survey-mis-2018/ (accessed
851	November 25 2020)
852	45 Ippolito MM Gebhardt ME Ferriss E et al Scientific Findings of the Southern and
853	Central Africa International Center of Excellence for Malaria Research: Ten Years of Malaria
854	Control Impact Assessments in Hypo- Meso- and Holoendemic Transmission Zones in Zambia
855	and Zimbabwe The American Journal of Tropical Medicine and Hysiene 2022: 107(4 Suppl):
856	55-67
857	46 Fola AA, Dorman J, Levy M, Ciubotariu I, Carpi G, Optimized HT gDNA extraction
858	from Dried Blood Spot using OIAcube HT for Malaria Genomic Epidemiology Studies 2020
859	https://www.protocols.io/view/optimized-ht-gdna-extraction-from-dried-blood-spot-
860	i8nlkei3115r/v1.
861	47. Choudhary S. pysradb: A Python package to query next-generation sequencing metadata
862	and data from NCBI Sequence Read Archive [version 1: peer review: 2 approved].
863	<i>F1000Research</i> 2019: 8 (532).
864	48. Carpi G. Gorenstein L. Harkins TT. Samadi M. Vats P. A GPU-accelerated compute
865	framework for pathogen genomic variant identification to aid genomic epidemiology of
866	infectious disease: a malaria case study <i>Briefings in Bioinformatics</i> 2022: 23(5)
867	49 Li H Aligning sequence reads clone sequences and assembly contigs with BWA-MEM
868	arXiv: Genomics 2013
869	50 McKenna A Hanna M Banks E et al The Genome Analysis Toolkit: a ManReduce
870	framework for analyzing next-generation DNA sequencing data Genome Res 2010: 20(9): 1297-
871	303.
872	51. DePristo MA, Banks E, Poplin R, et al. A framework for variation discovery and
873	genotyping using next-generation DNA sequencing data Nat Genet 2011: 43(5): 491-8

874	52. Miles A, Iqbal Z, Vauterin P, et al. Indels, structural variation, and recombination drive
875	genomic diversity in Plasmodium falciparum. Genome Res 2016; 26(9): 1288-99.
876	53. Cingolani P, Platts A, Wang LL, et al. A program for annotating and predicting the
877	effects of single nucleotide polymorphisms, SnpEff, <i>Fly</i> 2012; 6 (2); 80-92.
878	54. Manske M. Miotto O. Campino S. et al. Analysis of Plasmodium falciparum diversity in
879	natural infections by deep sequencing. <i>Nature</i> 2012: 487 (7407): 375-9.
880	55. Rausch KM, Barnafo EK, Lambert LE, et al. Preclinical evaluations of Pfs25-EPA and
881	Pfs230D1-EPA in AS01 for a vaccine to reduce malaria transmission. <i>iScience</i> 2023; 26 (7).
882	56. Duffy PE. The Virtues and Vices of Pfs230: From Vaccine Concept to Vaccine
883	Candidate. The American Journal of Tropical Medicine and Hygiene 2022; 107 (3 Suppl): 17-21
884	57. Silk SE, Kalinga WF, Mtaka IM, et al. Superior antibody immunogenicity of a viral-
885	vectored RH5 blood-stage malaria vaccine in Tanzanian infants as compared to adults. <i>Med</i>
886	2023.
887	58. Schwartz L, Brown GV, Genton B, Moorthy VS. A review of malaria vaccine clinical
888	projects based on the WHO rainbow table. <i>Malaria Journal</i> 2012; 11 (1): 11.
889	59. Molina-Cruz A, Barillas-Mury C. Pfs47 as a Malaria Transmission-Blocking Vaccine
890	Target. The American Journal of Tropical Medicine and Hygiene 2022; 107(3_Suppl): 27-31.
891	60. Rozas J, Ferrer-Mata A, Sánchez-DelBarrio JC, et al. DnaSP 6: DNA Sequence
892	Polymorphism Analysis of Large Data Sets. <i>Molecular Biology and Evolution</i> 2017; 34 (12):
893	3299-302.
894	61. Nei M, Li WH. Mathematical model for studying genetic variation in terms of restriction
895	endonucleases. Proceedings of the National Academy of Sciences 1979; 76(10): 5269-73.
896	62. Tajima F. Statistical method for testing the neutral mutation hypothesis by DNA
897	polymorphism. <i>Genetics</i> 1989; 123 (3): 585-95.
898	63. Nei M, Tajima F. DNA polymorphism detectable by restriction endonucleases. <i>Genetics</i>
899	1981; 97 (1): 145-63.
900	64. Leigh JW, Bryant D. popart: full-feature software for haplotype network construction.
901	<i>Methods in Ecology and Evolution</i> 2015; 6 (9): 1110-6.
902	65. Clement M, Snell Q, Walke P, Posada D, Crandall K. TCS: estimating gene genealogies.
903	Proceedings 16th International Parallel and Distributed Processing Symposium; 2002 15-19
904	April 2002; 2002. p. 7 pp.
905	66. Jumper J, Evans R, Pritzel A, et al. Highly accurate protein structure prediction with
906	AlphaFold. <i>Nature</i> 2021; 596 (7873): 583-9.
907	67. Reva BA, Finkelstein AV, Skolnick J. What is the probability of a chance prediction of a
908	protein structure with an rmsd of 6 å? <i>Folding and Design</i> 1998; 3 (2): 141-7.
909	68. Chotnia C, Lesk AM. The relation between the divergence of sequence and structure in $T_{\rm e}$ EMPO L $= 11096$ $F(4)$ 922 C
910	proteins. <i>The EMBO Journal</i> 1986; 5 (4): 823-6.
911	69. Mirdita M, Schutze K, Moriwaki Y, Heo L, Ovchinnikov S, Steinegger M. Colabfold:
912	making protein folding accessible to all. <i>Nature Methods</i> 2022; 19 (6): 679-82.
915	70. Guy AJ, Italii V, Richards JS, Rainstand PA. Biostructiviap: a Pytholi tool for integration of protein structure and sequence based features. <i>Picinformatics</i> 2018; 24 (22): 2042.4
714 015	71 Guy A L Irani V Beeson IG et al Proteome wide manning of immune features onto
91J 016	Plasmodium protein three-dimensional structures. Scientific Penarts 2018, Q (1), 1255
Q17	72 Ramarai T Angel T Dratz FA Jassitis AI Mumay R Antigan antibody interface
018	properties: Composition residue interactions and features of 53 non-redundant structures
910 910	Riochimica et Rionhysica Acta (RRA) - Proteins and Proteomics 2012: 182 A(3): 520-32
717	<i>Diochanaca ci Diophysica Acia (DDA) - 1 totenis ana 1 toteonacs 2012</i> , 102 (<i>3)</i> , <i>320-32</i> .

45

920 MalariaGEN. Genomic epidemiology of artemisinin resistant malaria. *eLife* 2016; 5: 73. 921 e08714. 922 74. Beutler N, Pholcharee T, Oyen D, et al. A novel CSP C-terminal epitope targeted by an 923 antibody with protective activity against Plasmodium falciparum. *PLOS Pathogens* 2022; **18**(3): 924 e1010409. 925 75. Coley AM, Gupta A, Murphy VJ, et al. Structure of the Malaria Antigen AMA1 in 926 Complex with a Growth-Inhibitory Antibody. *PLOS Pathogens* 2007; **3**(9): e138. 927 Bai T, Becker M, Gupta A, et al. Structure of AMA1 from Plasmodium falciparum 76. 928 reveals a clustering of polymorphisms that surround a conserved hydrophobic pocket. Proc Natl 929 Acad Sci U S A 2005; 102(36): 12736-41. 930 77. Dutta S, Lee SY, Batchelor AH, Lanar DE. Structural basis of antigenic escape of a 931 malaria vaccine candidate. Proceedings of the National Academy of Sciences of the United States 932 of America 2007; 104(30): 12488-93. 933 78. Jimah JR, Salinas ND, Sala-Rabanal M, et al. Malaria parasite CelTOS targets the inner 934 leaflet of cell membranes for pore-dependent disruption. *Elife* 2016; 5. 935 79. Patel PN, Dickey TH, Hopp CS, et al. Neutralizing and interfering human antibodies 936 define the structural and mechanistic basis for antigenic diversion. *Nature Communications* 937 2022; 13(1): 5888. 938 Wright KE, Hjerrild KA, Bartlett J, et al. Structure of malaria invasion protein RH5 with 80. 939 erythrocyte basigin and blocking antibodies. Nature 2014; 515(7527): 427-30. 940 Alanine DGW, Quinkert D, Kumarasingha R, et al. Human Antibodies that Slow 81. 941 Erythrocyte Invasion Potentiate Malaria-Neutralizing Antibodies. Cell 2019; 178(1): 216-28.e21. 942 82. Ragotte RJ, Pulido D, Lias AM, et al. Heterotypic interactions drive antibody synergy 943 against a malaria vaccine candidate. *Nature Communications* 2022; **13**(1): 933. 944 Lennartz F, Brod F, Dabbs R, et al. Structural basis for recognition of the malaria vaccine 83. 945 candidate Pfs48/45 by a transmission blocking antibody. *Nature Communications* 2018; 9(1): 946 3822. 947 84. Ochwedo KO, Onyango SA, Omondi CJ, et al. Signatures of selection and drivers for 948 novel mutation on transmission-blocking vaccine candidate Pfs25 gene in western Kenya. PLOS 949 ONE 2022; 17(4): e0266394. 950 85. Kaslow DC, Quakyi IA, Keister DB. Minimal variation in a vaccine candidate from the 951 sexual stage of Plasmodium falciparum. *Molecular and Biochemical Parasitology* 1989; **32**(1): 952 101-3. 953 86. Duffy PE, Kaslow DC. A novel malaria protein, Pfs28, and Pfs25 are genetically linked 954 and synergistic as falciparum malaria transmission-blocking vaccines. Infection and Immunity 955 1997; 65(3): 1109-13. 956 87. Singh K, Burkhardt M, Nakuchima S, et al. Structure and function of a malaria 957 transmission blocking vaccine targeting Pfs230 and Pfs230-Pfs48/45 proteins. Communications 958 *Biology* 2020; **3**(1): 395. 959 Weiss GE, Crabb BS, Gilson PR. Overlaying Molecular and Temporal Aspects of 88. 960 Malaria Parasite Invasion. *Trends in Parasitology* 2016; **32**(4): 284-95. 961 Scally SW, Murugan R, Bosch A, et al. Rare PfCSP C-terminal antibodies induced by 89. 962 live sporozoite vaccination are ineffective against malaria infection. Journal of Experimental 963 *Medicine* 2017; **215**(1): 63-75.

46

964 90. Pholcharee T, Oyen D, Flores-Garcia Y, et al. Structural and biophysical correlation of
965 anti-NANP antibodies with in vivo protection against P. falciparum. *Nature Communications*966 2021; **12**(1): 1063.
967 91. Basu M, Maji AK, Mitra M, Sengupta S. Natural selection and population genetic
968 structure of domain-I of Plasmodium falciparum apical membrane antigen-1 in India. *Infection,*969 *Genetics and Evolution* 2013; **18**: 247-56.
970 92 Colling CD. Withers Martinger C. Heckett F. Plackmap MI. An Inhibitory Antibody.

- 970 92. Collins CR, Withers-Martinez C, Hackett F, Blackman MJ. An Inhibitory Antibody
- Blocks Interactions between Components of the Malarial Invasion Machinery. *PLOS Pathogens*2009; 5(1): e1000273.
- 973 93. Ghoshal S, Chowdhury P, Ray S, et al. Population genetic and biophysical evidences 974 reveal that purifying selection shapes the genetic landscape of Plasmodium falciparum RH
- 975 ligands in Chhattisgarh and West Bengal, India. *Malaria Journal* 2020; **19**(1): 367.
- 976 94. van Schaijk BCL, van Dijk MR, van de Vegte-Bolmer M, et al. Pfs47, paralog of the
- male fertility factor Pfs48/45, is a female specific surface protein in Plasmodium falciparum. *Molecular and Biochemical Parasitology* 2006; 149(2): 216-22.
- 979 95. van Dijk MR, Janse CJ, Thompson J, et al. A Central Role for P48/45 in Malaria Parasite 980 Male Gamete Fertility. *Cell* 2001; **104**(1): 153-64.
- 981 96. Eksi S, Czesny B, Van Gemert G-J, Sauerwein RW, Eling W, Williamson KC. Malaria
 982 transmission-blocking antigen, Pfs230, mediates human red blood cell binding to exflagellating
 983 male parasites and oocyst production. *Molecular Microbiology* 2006; 61(4): 991-8.
- 984 97. Fabra-García A, Hailemariam S, de Jong RM, et al. Highly potent, naturally acquired 985 human monoclonal antibodies against Pfs48/45 block Plasmodium falciparum transmission to 986 mosquitoes. *Immunity* 2023; **56**(2): 406-19.e7.
- 987 98. Ko K-T, Lennartz F, Mekhaiel D, et al. Structure of the malaria vaccine candidate
- Pfs48/45 and its recognition by transmission blocking antibodies. *Nature Communications* 2022; **13**(1): 5603.
- 990
 99. Coelho CH, Tang WK, Burkhardt M, et al. A human monoclonal antibody blocks malaria
 991 transmission and defines a highly conserved neutralizing epitope on gametes. *Nature* 992 Communication (1992) 12(1): 1750
- 992 *Communications* 2021; **12**(1): 1750.
- 100. Ivanochko D, Fabra-García A, Teelen K, et al. Potent transmission-blocking monoclonal
 antibodies from naturally exposed individuals target a conserved epitope on Plasmodium
 falciparum Pfs230. *Immunity* 2023; 56(2): 420-32.e7.
- 101. Tang WK, Coelho CH, Miura K, et al. A human antibody epitope map of Pfs230D1
- 997 derived from analysis of individuals vaccinated with a malaria transmission-blocking vaccine.

998 *Immunity* 2023; **56**(2): 433-43.e5.

- 102. Canepa GE, Molina-Cruz A, Yenkoidiok-Douti L, et al. Antibody targeting of a specific
 region of Pfs47 blocks Plasmodium falciparum malaria transmission. *npj Vaccines* 2018; **3**(1):
- 1001 26.
- 1002 103. Stowers AW, Keister DB, Muratova O, Kaslow DC. A Region of <i>Plasmodium
- falciparum</i>Antigen Pfs25 That Is the Target of Highly Potent Transmission-Blocking
 Antibodies. *Infection and Immunity* 2000; 68(10): 5530-8.
- 1005 104. Kaslow DC. Immunogenicity of Plasmodium falciparum sexual stage antigens:
- 1006 Implications for the design of a transmission blocking vaccine. *Immunology Letters* 1990; 25(1):
 1007 83-6.

Barr PJ, Green KM, Gibson HL, Bathurst IC, Quakyi IA, Kaslow DC. Recombinant

47

- 1009 Pfs25 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in 1010 experimental animals. Journal of Experimental Medicine 1991; 174(5): 1203-8. 1011 Miura K, Keister DB, Muratova OV, Sattabongkot J, Long CA, Saul A. Transmission-106. 1012 blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable 1013 function of antibody titer. *Malaria Journal* 2007; **6**(1): 107. 1014 Scally SW, McLeod B, Bosch A, et al. Molecular definition of multiple sites of antibody 107. 1015 inhibition of malaria transmission-blocking vaccine antigen Pfs25. Nature Communications 1016 2017; 8(1): 1568. 1017 McLeod B, Miura K, Scally SW, et al. Potent antibody lineage against malaria 108. 1018 transmission elicited by human vaccination with Pfs25. *Nature Communications* 2019; **10**(1): 1019 4328. 1020 109. Gozar MMG, Price VL, Kaslow DC. Saccharomyces cerevisiae-Secreted Fusion Proteins
- Pfs25 and Pfs28 Elicit Potent Plasmodium falciparum Transmission-Blocking Antibodies in
 Mice. *Infection and Immunity* 1998; 66(1): 59-64.
- 1022 Infection and Immunity 1998, **66**(1), 59-64. 1023 110. Qian F, Aebig JA, Reiter K, et al. Enhanced antibody responses to Plasmodium

1008

105.

- 1025 110. Qian F, Aeolg JA, Ketter K, et al. Enhanced antibody responses to Plasmodium 1024 falciparum Pfs28 induced in mice by conjugation to ExoProtein A of Pseudomonas aeruginosa
- 1025 with an improved procedure. *Microbes and Infection* 2009; **11**(3): 408-12.
- 1026 111. Menon V, Kapulu MC, Taylor I, et al. Assessment of Antibodies Induced by Multivalent 1027 Transmission-Blocking Malaria Vaccines. *Frontiers in Immunology* 2018; **8**.
- 1028 112. Gregory JA, Li F, Tomosada LM, et al. Algae-Produced Pfs25 Elicits Antibodies That
- 1029 Inhibit Malaria Transmission. *PLOS ONE* 2012; **7**(5): e37179.
- 1030 113. Pirahmadi S, Zakeri S, A. Mehrizi A, et al. Cell-traversal protein for ookinetes and
- 1031 sporozoites (CelTOS) formulated with potent TLR adjuvants induces high-affinity antibodies
- that inhibit Plasmodium falciparum infection in Anopheles stephensi. *Malaria Journal* 2019; **18**(1): 146.
- 1034 114. Chen L, Xu Y, Healer J, et al. Crystal structure of PfRh5, an essential P. falciparum 1035 ligand for invasion of human erythrocytes. *eLife* 2014; **3**: e04187.
- 1036 115. Campeotto I, Goldenzweig A, Davey J, et al. One-step design of a stable variant of the
 1037 malaria invasion protein RH5 for use as a vaccine immunogen. *Proceedings of the National*1038 *Academy of Sciences* 2017; **114**(5): 998-1002.
- 1039 116. Pizarro JC, Chitarra V, Verger D, et al. Crystal Structure of a Fab Complex Formed with
- 1040 PfMSP1-19, the C-terminal Fragment of Merozoite Surface Protein 1 from Plasmodium
- falciparum: A Malaria Vaccine Candidate. *Journal of Molecular Biology* 2003; **328**(5): 10911042 103.
- 1043 117. Thouvenel CD, Fontana MF, Netland J, et al. Multimeric antibodies from antigen-
- specific human IgM+ memory B cells restrict Plasmodium parasites. *Journal of Experimental Medicine* 2021; 218(4).
- 1046 118. MacDonald NJ, Singh K, Reiter K, et al. Structural and immunological differences in
- Plasmodium falciparum sexual stage transmission-blocking vaccines comprised of Pfs25-EPA
 nanoparticles. *npj Vaccines* 2023; 8(1): 56.
- 1049 119. McLeod B, Mabrouk MT, Miura K, et al. Vaccination with a structure-based stabilized
- version of malarial antigen Pfs48/45 elicits ultra-potent transmission-blocking antibody
 responses. *Immunity* 2022; 55(9): 1680-92.e8.
- 1052 120. Kundu P, Semesi A, Jore MM, et al. Structural delineation of potent transmission-
- 1053 blocking epitope I on malaria antigen Pfs48/45. *Nature Communications* 2018; **9**(1): 4458.

1054 Shukla N, Tang WK, Tolia NH. Structural analysis of Plasmodium falciparum ookinete 121. 1055 surface antigen Pfs28 relevant for malaria vaccine design. Scientific Reports 2022; 12(1): 19556. 1056